Close Menu

irritable bowel syndrome

NEW YORK (GenomeWeb News) – Olink Bioscience today announced a consortium formed to advance research into inflammatory bowel diseases.

Norwegian molecular diagnostics firm Genetic Analysis announced two new developments last week. The first was the appointment of Kari Stenerson, a former Axis-Shield marketing director, as its new CEO.

Researchers led by a group at Beth Israel Deaconess Medical Center have identified a genetic marker associated with the placebo effect in patients with irritable bowel syndrome.

The exclusive sales and marketing agreement covers gene expression tests for inflammatory bowel disease and irritable bowel syndrome.

The first version of the sequencer, about to enter beta-testing, will cost around $250,000 and will be able to generate several gigabases of data in a 5.5-hour run with $250 in consumables costs per gigabase. That price is expected to fall to as little as $2 with later generations.

Battelle Ventures, MIT, Hepragen, Wayne State University, Defyrus, UK Ministry of Defence, Columbia U, Intelligent Bio-Systems, Kauffman Foundation

Short Reads: Feb 24, 2009

Premium

Intelligent Bio-Systems, Norwich Ventures, National Human Genome Research Institute, Floragenex, National Center for Genome Resources, Decode Genetics, DNAStar, Infogen

IBS has kept a relatively low profile the past couple of years, but it plans to get prototype sequencing systems into the hands of early-access customers as early as the first quartyer of this year.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.